tiprankstipranks
Brickell Biotech (BBI)
NASDAQ:BBI

Brickell Biotech Stock Analysis & Ratings

BBI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.09 - $5.10
Previous Close$3.98
Volume803.98K
Average Volume (3M)166.62K
Market CapN/A
Enterprise ValueN/A
P/E Ratio>-0.1
Beta0.50
Next EarningsAug 17, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart ScoreN/A


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

BBI FAQ

What was Brickell Biotech’s price range in the past 12 months?
Brickell Biotech lowest stock price was $0.09 and its highest was $5.10 in the past 12 months.
    What is Brickell Biotech’s market cap?
    Currently, no data Available
    What is Brickell Biotech’s price target?
    The average price target for Brickell Biotech is $0.63. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $1.00 ,the lowest forecast is $0.25. The average price target represents -84.17% Decrease from the current price of $3.98.
      What do analysts say about Brickell Biotech?
      Brickell Biotech’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
        When is Brickell Biotech’s upcoming earnings report date?
        Brickell Biotech’s upcoming earnings report date is Aug 17, 2022 which is in 41 days.
          How were Brickell Biotech’s earnings last quarter?
          Brickell Biotech released its earnings results on May 12, 2022. The company reported -$3.6 earnings per share for the quarter, missing the consensus estimate of -$2.588 by -$1.012.
            Is Brickell Biotech overvalued?
            According to Wall Street analysts Brickell Biotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
              Does Brickell Biotech pay dividends?
              Brickell Biotech does not currently pay dividends.
              What is Brickell Biotech’s EPS estimate?
              Brickell Biotech’s EPS estimate is -$1.5.
                How many shares outstanding does Brickell Biotech have?
                Brickell Biotech has 2,653,686 shares outstanding.
                  What happened to Brickell Biotech’s price movement after its last earnings report?
                  Brickell Biotech reported an EPS of -$3.6 in its last earnings report, missing expectations of -$2.588. Following the earnings report the stock price went down -9.989%.
                    Which hedge fund is a major shareholder of Brickell Biotech?
                    Currently, no hedge funds are holding shares in BBI

                    ---

                    Brickell Biotech Stock Analysis

                    Smart Score
                    N/A
                    Not Ranked
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10
                    Price Target
                    $0.63
                    ▼(-84.17% Downside)
                    Moderate Buy
                    This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Brickell Biotech

                    Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Sanofi-Aventis Sa
                    Chimerix
                    Novavax
                    Merck & Company
                    Bristol Myers

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis